J.P. Morgan analyst Anupam Rama has maintained their bullish stance on VERA stock, giving a Buy rating on September 19.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anupam Rama has given his Buy rating due to a combination of factors that highlight the potential of Vera Therapeutics’ atacicept in treating IgA nephropathy (IgAN). The upcoming fourth quarter is crucial as it will reveal the full 36-week results from the pivotal ORIGIN 3 study, which are anticipated to underscore atacicept’s differentiated clinical profile, particularly in terms of proteinuria and eGFR data. These results are expected to demonstrate atacicept’s competitive edge and long-term potential, contributing to the perception of VERA shares as undervalued.
Furthermore, the market dynamics surrounding IgAN treatments present additional opportunities for Vera Therapeutics. The potential for atacicept to capture a significant market share, coupled with its convenient administration as a weekly subcutaneous auto-injector, positions it favorably against competitors. The anticipated total addressable market for high-risk IgAN patients is substantial, and any setbacks faced by competitors like sibeprenlimab could further enhance VERA’s market position. These factors collectively support Anupam Rama’s optimistic outlook and Buy rating for Vera Therapeutics.
In another report released on September 19, LifeSci Capital also maintained a Buy rating on the stock with a $70.00 price target.